Published in Kidney Int on June 07, 2016
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. Front Oncol (2016) 0.82
Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken) (2016) 0.82
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol (2017) 0.81
Role of Oxidative Stress in Drug-Induced Kidney Injury. Int J Mol Sci (2016) 0.79
[The pathology of adverse events with immune checkpoint inhibitors]. Pathologe (2017) 0.78
Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer (2016) 0.75
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol (2016) 0.75
Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int (2008) 6.04
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol (2015) 2.60
Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) (2011) 2.25
Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant (2004) 2.20
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol (2006) 1.62
Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis (2014) 1.42
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer (2014) 1.32
Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol (2009) 1.31
Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med (2009) 1.30
Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev (2016) 1.15
Negative regulation of T-cell function by PD-1. Crit Rev Immunol (2004) 1.11
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Ipilimumab-induced immune-related renal failure--a case report. Anticancer Res (2012) 1.00
Ipilimumab granulomatous interstitial nephritis. Am J Ther (2015) 0.89
The role of tubulointerstitial inflammation. Kidney Int Suppl (2005) 0.87
Kinetic eGFR and Novel AKI Biomarkers to Predict Renal Recovery. Clin J Am Soc Nephrol (2015) 0.86
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res (2016) 0.86
Combinatorial cancer immunotherapy. Adv Immunol (2006) 0.93
Lenalidomide-induced acute interstitial nephritis. Oncologist (2010) 0.75